ARTICLE | Company News
Ablitech musculoskeletal, drug delivery news
October 17, 2011 7:00 AM UTC
The U.S. Department of Defense granted Ablitech a $2 million grant to develop its Versadel short interfering RNA delivery technology to treat heterotopic ossification, a random painful growth that occ...